	US 12,448,431 B2
	Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein
Daniel J. Powell, Jr., Bala Cynwyd, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Apr. 29, 2022, as Appl. No. 17/733,226.
Application 17/733,226 is a division of application No. 16/534,344, filed on Aug. 7, 2019, granted, now 11,345,735.
Application 16/534,344 is a division of application No. 15/550,811, granted, now 10,414,812, issued on Sep. 17, 2019, previously published as PCT/US2016/017521, filed on Feb. 11, 2016.
Claims priority of provisional application 62/116,864, filed on Feb. 16, 2015.
Prior Publication US 2022/0332787 A1, Oct. 20, 2022
Int. Cl. C07K 14/725 (2006.01); C07K 14/47 (2006.01); C07K 14/82 (2006.01); C07K 16/28 (2006.01); C12N 9/12 (2006.01)

CPC C07K 14/7051 (2013.01) [C07K 14/4705 (2013.01); C07K 14/82 (2013.01); C07K 16/28 (2013.01); C12N 9/12 (2013.01)]

20 Claims

1. A purified T cell receptor (TCR) having affinity for a tyrosine-protein kinase HER2/Neu (ERBB2) on a target cell, wherein the purified TCR comprises: a TCR alpha chain comprising the amino acid sequence set forth in SEQ ID NO: 6 and a TCR beta chain comprising the amino acid sequence set forth in SEQ ID NO:7.